TY - JOUR
T1 - ALDH5A1 variability in opioid dependent patients could influence response to methadone treatment
AU - Fonseca, Francina
AU - Gratacòs, Mònica
AU - Escaramís, Geòrgia
AU - De Cid, Rafael
AU - Martín-Santos, Rocío
AU - Farré, Magi
AU - Estivill, Xavier
AU - Torrens, Marta
PY - 2014/3/1
Y1 - 2014/3/1
N2 - Methadone maintenance treatment is the most widely-used therapy in opioid dependence, but some patients relapse or drop out from treatment. We genotyped a genetic variant in the succinic semialdehyde dehydrogenase enzyme gene, ALDH5A1, and found that subjects carrying the T variant allele have a higher risk to be nonresponders to methadone treatment (OR=3.16; 95% CI [1.48-6.73], P=0.0024). This could be due to a reduction in the ALDH5A1 enzyme activity, that would increase endogenous gamma-hydroxbutyric acid (GHB) and gamma-aminobutyric acid (GABA) levels and therefore, inducing symptoms such as sedation and impaired pschomotor performance. These neuropsychological effects related with the reduction in enzyme activity could be responsible for a higher propensity to relapse in these genetically predisposed patients. © 2013 Elsevier B.V. and ECNP.
AB - Methadone maintenance treatment is the most widely-used therapy in opioid dependence, but some patients relapse or drop out from treatment. We genotyped a genetic variant in the succinic semialdehyde dehydrogenase enzyme gene, ALDH5A1, and found that subjects carrying the T variant allele have a higher risk to be nonresponders to methadone treatment (OR=3.16; 95% CI [1.48-6.73], P=0.0024). This could be due to a reduction in the ALDH5A1 enzyme activity, that would increase endogenous gamma-hydroxbutyric acid (GHB) and gamma-aminobutyric acid (GABA) levels and therefore, inducing symptoms such as sedation and impaired pschomotor performance. These neuropsychological effects related with the reduction in enzyme activity could be responsible for a higher propensity to relapse in these genetically predisposed patients. © 2013 Elsevier B.V. and ECNP.
KW - ALDH5A1 gene
KW - Gamma-aminobutyric acid
KW - Gamma-hydroxibutyric acid (GHB)
KW - Methadone maintenance treatment (MMT)
KW - Opioid dependence
KW - Pharmacogenetics
U2 - 10.1016/j.euroneuro.2013.10.003
DO - 10.1016/j.euroneuro.2013.10.003
M3 - Article
SN - 0924-977X
VL - 24
SP - 420
EP - 424
JO - European Neuropsychopharmacology
JF - European Neuropsychopharmacology
IS - 3
ER -